Use and abuse of methylphenidate in attention-deficit/hyperactivity disorder

Canadian Pharmaceutical Journal

Volumn 137, Issue 6, 2004, Pages 30-35

  Evans, Charity ^a   Blackburn, David ^b   Butt, Peter ^b   Dattani, Dan ^b  

^a Stueck Pharmacy   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTICONVULSIVE AGENT; ATOMOXETINE; ATTENADE; CENTRAL STIMULANT AGENT; CLONIDINE; COCAINE; COUMARIN ANTICOAGULANT; DESIPRAMINE; DEXMETHYLPHENIDATE; HYDROMORPHONE; IMIPRAMINE; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; MORPHINE; PENTAZOCINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANOREXIA; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; DRUG ABUSE; DRUG ALCOHOL INTERACTION; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSAGE FORM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INTERMITTENT THERAPY; DRUG MISUSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; FOLLOW UP; GROWTH RETARDATION; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MOOD DISORDER; NERVOUSNESS; PATIENT MONITORING; PRESCRIPTION; REBOUND; REVIEW; SADNESS; SEIZURE; SIDE EFFECT; STOMACH PAIN; SUSTAINED RELEASE PREPARATION; TIC;

EID: 4544246443     PISSN: 08286914     EISSN: None     Source Type: Journal    
DOI: 10.1177/171516350413700606     Document Type: Review

References (36)

1. American Academy of Pediatrics, Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics 2001;108:1033-44.
2. Greenhill LL, Pliska S, Dulcan MK, et al, for the American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41:26S-49S.
3. Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit- hyperactivity disorder. N Engl J Med 1999;340:780-8.
4. Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc 2000;75:711-21.
5. Rappley MD. Safety issues in the use of methylphenidate. An American perspective. Drug Saf 1997;17:143-8.
6. Barkley RA, McMurray MB, Edelbrock CS, et al. Side effects of methylphenidate in children with attention-deficit/hyperactivity disorder: a systematic, placebo-controlled evaluation. Pediatrics 1990;86:184-92.
7. Ahman PA, Waltonen SJ, Olson KA, et al. Placebo-controlled evaluation of Ritalin side effects. Pediatrics 1993;91:1101-6.
8. Feeney DJ, Klyklo WM. Medication-induced seizures [letter]. J Am Acad Child Adolesc Psychiatry 1997;36:1018-9.
9. Schteinschnaider A, Plaghos LL, Garbugina S, et al. Cerebral arteritis following methylphenidate use. J Child Neurol 2000;15:265-7.
10. Kotsopoulos S, Spivak M. Obsessive-compulsive symptoms secondary to methylphenidate treatment [letter]. Can J Psychiatry 2001;46:89.
11. Kouris S. Methylphenidate-induced obsessive compulsiveness [letter]. J Am Acad Child Adolesc Psychiatry 1998;37:135.
12. Adrian N. Explosive outbursts associated with methylphenidate [letter]. J Am Acad Child Adolesc Psychiatry 2001;40:618-9.
13. Satterfield JH, Cantwell DP, Schell A, et al. Growth of hyperactive children treated with methylphenidate. Arch Gen Psychiatry 1979;36:212-7.
14. Gittelman R, Klein RG, Manuzza S. Hyperactive boys almost grown up. Arch Gen Psychiatry 1988;45:1131-4.
15. Manuzza S, Klein RG. Long-term prognosis in attention-deficit/ hyperactivity disorder. Child Adolesc Psychiatry Clin North Am 2000;9:711-26.
16. Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 1998;31:533-44.
17. Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999;104:e20.
18. Manuzza S, Klein RG, Bonagura N, et al. Hyperactive boys almost grown up v. replication of psychiatric status. Arch Gen Psychiatry 1991;48:77-83.
19. Prescribing information: Ritalin® (methylphenidate hydrochloride) 10 mg and 20 mg tablets Novartis standard and Ritalin® SR (methylphenidate hydrochloride extended-release tablets) 20 mg tablets Novartis standard. Dorval (QC): Novartis Pharmaceuticals Canada Inc.; 1999 Dec 15. Available: www.pharma.ca. novartis.com/downloads/e/ritalin_scrip_e.pdf (accessed June 21, 2004).
20. Gross-Tsur B, Manor O, Van der Meere J, et al. Epilepsy and attention-deficit/hyperactivity disorder: is methylphenidate safe and effective? J Pediatr 1997;130:40-4.
21. DEA congressional testimony. Statement by Terrance Woodworth before the Committee on Education and the Workforce: Subcommittee on Early Childhood, Youth and Families (electronic). Alexandria (VA): US Drug Enforcement Administration; 2000 May 16. Available: www.usdoj.gov/dea/pubs/cngrtest/ct051600.htm (accessed June 21, 2004).
22. Volkow ND, Yu-Shin D, Fowler JS, et al. Is methylphenidate like cocaine? Arch Gen Psychiatry 1995;52:456-63.
23. Volkow N, Wang GJ, Fowler JS, et al. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci 1999;65:7-12.
24. Ritz MC, Lamb RJ, Goldberg SR, et al. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987;237:1219-23.
25. Bergman J, Madras BK, Johnson SE. Effects of cocaine and related drugs in nonhuman primates. III Self-administration by squirrel monkeys. J Pharmacol Exp Ther 1989;251:150-5.
26. Liana ME, Crismon ML. Methylphenidate: Increased abuse or appropriate use? J Am Pharm Assoc 1999;39:526-30.
27. Lucas PB, Gardner DL, Wolkowitz OM, et al. Methylphenidate-induced cardiac arrhythmias [letter]. N Engl J Med 1986;315:1485.
28. Parran TV, Jasinski DR. Intravenous methylphenidate abuse. Prototype for prescription drug abuse. Arch Intern Med 1991;151:781-3.
29. Lewman LV. Fatal pulmonary hypertension from intravenous injection of methylphenidate (Ritalin) tablets. Hum Pathol 1972;3:67-70.
30. Carter HS, Watson WA. IV pentazocine/methylphenidate abuse - the clinical toxicity of another Ts and blues combination. J Toxicol Clin Toxicol 1994;32:541-7.
31. Garland EJ. Intranasal abuse of prescribed methylphenidate. J Am Acad Child Adolesc Psychiatry 1998;37:573-4.
32. Jaffe SL. Intranasal abuse of prescribed methylphenidate by an alcohol and drug abusing adolescent with ADHD. J Am Acad Child Adolesc Psychiatry 1991;30:773-5.
33. Massello W 3rd, Carpenter DA. A fatality due to the intranasal abuse of methylphenidate (Ritalin®). J Forensic Sci 1999;44:220-1.
34. Corrigall R, Ford T. Methylphenidate euphoria [letter]. J Am Acad Child Adolesc Psychiatry 1996;35:1421.
35. Goyer PF, Davis GC, Rapoport JL. Abuse of prescribed stimulant medication by a 13-year-old hyperactive boy. Am Acad Child Psychiatry 1979;18:170-5.
36. Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998;155:1325-31.